Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Methylphenidate for PTSD With Neurocognitive Complaints
NCT05776056Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in post-traumatic stress disorder (PTSD) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: PTSD Symptom Checklist for DSM-5 at 4 weeks. Started Feb 2024; status: recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05776056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776056.